Author

Yi-Zhou Jiang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Current and future therapies for triple-negative breast cancer

This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...

Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al. · Journal of Hematology & Onco... · 0 citations

Open access Jul 2026

ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition

A role of ZNF689 is identified in regulation of homologous recombination repair via stabilization of the MRN complex, with ZNF689 deficiency conferring sensitivity to PARP inhibition, which upregulates PD-L1 expression and sensitizes tumors to combination therapy with anti-PD-L1 in TNBC.

Li-Ping Ge, Yu-Ling Xiao, Song-Yang Wu et al. · Nature Communications · 0 citations